Skip to main content

Table 1 Patients clinico-pathological characteristics according to SLNB (n = 402)

From: Head and neck melanoma: outcome and predictors in a population-based cohort study

  SLNB χ2
no yes total p
Count % Count % Count %
Sex Male 170 52.6% 57 72.2% 227 56.5% 0.002
Female 153 47.4% 22 27.8% 175 43.5%
Age at diagnosis <  50.0 51 15.8% 21 26.6% 72 17.9% 0.006
50.0–59.9 47 14.6% 12 15.2% 59 14.7%
60.0–69.9 68 21.1% 12 15.2% 80 19.9%
70.0–79.9 95 29.4% 30 38.0% 125 31.1%
≥ 80.0 62 19.2% 4 5.1% 66 16.4%
CCI 0 239 74.0% 57 72.2% 296 73.6% 0.530
1 57 17.6% 16 20.3% 73 18.2%
2 19 5.9% 3 3.8% 22 5.5%
3 4 1.2% 3 3.8% 7 1.7%
4 3 0.9% 0 0.0% 3 0.7%
5 1 0.3% 0 0.0% 1 0.2%
CCI classified 0 239 74.0% 57 72.2% 296 73.6% 0.739
≥ 1 84 26.0% 22 27.8% 106 26.4%
Tumor localisation (ICD-10) Lip skin (C44.0) 2 0.6% 0 0.0% 2 0.5% 0.062
Eyelid (C44.1) 16 5.0% 2 2.5% 18 4.5%
Outer ear (C44.2) 44 13.6% 17 21.5% 61 15.2%
Face (C44.3) 163 50.5% 28 35.4% 191 47.5%
Scalp and neck (C44.4) 98 30.3% 32 40.5% 130 32.3%
Tumor localisation Face 225 69.7% 47 59.5% 272 67.7% 0.083
Scalp and neck 98 30.3% 32 40.5% 130 32.3%
UICC stage IA 214 66.3% 5 6.3% 219 54.5% <  0.001
IB 51 15.8% 21 26.6% 72 17.9%
II 48 14.9% 43 54.4% 91 22.6%
III 10 3.1% 10 12.7% 20 5.0%
Histological subgroups Lentigo maligna melanoma 156 48.3% 10 12.7% 166 41.3% <  0.001
Nodular melanoma 34 10.5% 27 34.2% 61 15.2%
Superficial spreading melanoma 104 32.2% 22 27.8% 126 31.3%
Melanoma not otherwise specified 22 6.8% 11 13.9% 33 8.2%
Other 7 2.2% 9 11.4% 16 4.0%
Tumor thickness (mm) <  1 232 71.8% 11 13.9% 243 60.4% <  0.001
1–2 39 12.1% 26 32.9% 65 16.2%
2–4 28 8.7% 16 20.3% 44 10.9%
>  4 24 7.4% 26 32.9% 50 12.4%
Resection margin (mm) <  5 83 25.7% 12 15.2% 95 23.6% <  0.001
5–9 137 42.4% 18 22.8% 155 38.6%
≥ 10 103 31.9% 49 62.0% 152 37.8%
Adjuvant Chemo−/ Immunotherapy yes 12 3.7% 6 7.6% 18 4.5% 0.135
no 311 96.3% 73 92.4% 384 95.5%
  total 323 100.0% 79 100.0% 402 100.0%